What’s Driving Growth in the Cholestatic Pruritus Market? Insights into Key Trends and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What is the Anticipated CAGR of the Cholestatic Pruritus Market, and What Factors Will Drive It?
The market size for cholestatic pruritus has witnessed robust expansion in the last few years. It is projected to amplify from $19.20 billion in 2024 to $20.28 billion in 2025, maintaining a compound annual growth rate (CAGR) of 5.6%. The growth throughout the historical period can be credited to the surge in incidents of skin conditions, an escalation in research and development investments, the call for effective treatments, heightened recognition of the sickness, and supportive regulatory conditions.
Anticipations point towards a robust expansion in the cholestatic pruritus market size in the coming years, with predictions reaching $24.97 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.3%. This projected development during the forecast period is primarily credited to the surge in the aged population, the escalating incidences of atopic dermatitis and urticaria, an increase in elderly population, the rise in chronic kidney maladies, and the expanding prevalence of conditions related to pruritus. Prominent trends projected during the forecast period encompass the emergence of new treatment alternatives, collaborations with leading enterprises for cholestasis pruritus investigation, revolutions in treatment methodologies, enhancement of healthcare facilities, and technological advancements.
What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Cholestatic Pruritus Market?
The escalating rates of liver disease are anticipated to stimulate the expansion of the cholestatic pruritus market in the future. There’s a wide spectrum of disorders – including infections, autoimmune diseases, genetic conditions, and toxin-induced damage – that jeopardizes the function of the liver, often birthing inflammation, scarring, or liver failure. The increasing occurrence of these liver conditions is spurred on by mounting obesity rates, diabetes, alcohol consumption, viral hepatitis infections, and prolonged exposure to harmful toxins and environmental influences. Cholestatic pruritus plays a vital role in detecting and managing liver diseases by emerging as a primary symptom signaling hindered bile flow, thus necessitating further examination and addressing of root hepatic problems. To illustrate, in July 2023, the Office for Health Improvement and Disparities, an entity of the UK government committed to mitigating health disparities, stated that hospital admissions for liver disease in England saw a 22% surge for the year ending in 2022, jumping from 67,458 to 82,290. Consequently, the rising incidence of liver diseases will be a catalyst for the expansion of the cholestatic pruritus market.
Explore Comprehensive Insights Into The Global Cholestatic Pruritus Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp
Who Are the Top Companies Contributing to the Growth of the Cholestatic Pruritus Market?
Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Incyte Corporation, Ipsen Pharma, Vanda Pharmaceuticals Inc., Medison Pharma Ltd., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Dipharma Francis S.r.l., Cara Therapeutics Inc., CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Tharimmune Inc., Vifor Fresenius Medical Care Renal Pharma, CymaBay Therapeutics Inc., ICE Pharma Inc., Aquatic Remedies Private Limited.
How Are Technological Trends Affecting the Growth and Development of the Cholestatic Pruritus Market?
Key players within the cholestatic pruritus market are investing in the creation of novel solutions to tackle symptoms, enhancing patient comfort, and provide targeted relief by addressing root causes such as bile salt accumulation and inflammation. Liquid formulations, or oral solutions, for cholestatic pruritus are being developed aimed at reducing bile acid buildup and soothing intense itching associated with cholestasis. For example, in March 2024, U.S. biopharmaceutical firm, Mirum Pharmaceuticals Inc., acquired approval from the U.S. Food and Drug Administration for LIVMARLI (maralixibat), an oral solution designed to treat cholestatic pruritus in patients aged five and up diagnosed with progressive familial intrahepatic cholestasis (PFIC). This daily, orally taken inhibitor of ileal bile acid transporter has secured breakthrough therapy status for PFIC type 2. LIVMARLI is set to greatly benefit patients dealing with cholestatic pruritus associated with PFIC, providing a much required therapy alternative for individuals with the rare subtypes.
Secure Your Global Cholestatic Pruritus Market Report Now for Fast and Efficient Delivery!
https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report
Which Segments of the Cholestatic Pruritus Market Hold the Most Potential for Future Development?
The cholestatic pruritus market covered in this report is segmented –
1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy (ICP), Other Disease Types
2) By Treatment Type: Medications, Phototherapy, Other Treatment Types
3) By Route Of Administration: Oral, Topical, Injectable
4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare
Subsegments:
1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure
2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures
3) By Intrahepatic Cholestasis of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk
4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders
What Are the Key Regions Powering Growth in the Cholestatic Pruritus Market?
North America was the largest region in the cholestatic pruritus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Defines the Scope of the Cholestatic Pruritus Market?
Cholestatic pruritus refers to severe itching caused by the buildup of bile acids in the skin, typically resulting from liver diseases that impair bile flow. This condition can significantly affect a patient’s quality of life and often requires targeted treatment to manage the discomfort and address the underlying liver dysfunction.
Browse Through More Similar Reports By The Business Research Company:
Histoplasmosis Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/histoplasmosis-treatment-global-market-report
Intestinal Pseudo-Obstruction Treatment Global Market Report 2025
Small Cell Lung Cancer Therapeutics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
